Shin Poong Pharmaceutical Co. Ltd.

Pharma

Seoul, South Korea, South Korea · Est. 1945

Shin Poong Pharmaceutical is a South Korean pharmaceutical company focused on developing and commercializing prescription and over-the-counter medications across multiple therapeutic areas.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

6 drugs in development

Phase 31

Phase 25

By Therapeutic Area

top 1

Cardiovascular

6100%

R&D Momentum

23/100

Pipeline Velocity

0/100

Trial Completion Rate

94/100

Pipeline Concentration

100/100

Pipeline Freshness

64/100

Strategic Signals

↗Early-stage heavy pipeline may seek late-stage partners

Activity

Key Events

Feb 14, 2025TrialEfficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care

Dec 5, 2024TrialEvaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension

Jun 12, 2024TrialEfficacy and Safety of SPC1001 in Patients With Essential Hypertension

Jul 24, 2022TrialPilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

Mar 25, 2022TrialEvaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension

Jan 1, 2022TrialA Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab

Oct 18, 2021TrialThe Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)

Apr 14, 2021TrialPivotal Study to Evaluate Efficacy and Safety of SP5M001 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis

4 more events

Mar 29, 2021TrialThe Safety and Efficacy of Pyronaridine-artesunate (Pyramax® or Artecom®)in COVID-19 Patients

Jan 3, 2021TrialA Phase I Study to Evaluate Safety and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8356

Sep 3, 2020TrialFour Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19

Jul 9, 2020TrialThe Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Founded1945

HQSeoul, South Korea, South Korea

Therapeutic Focus

GastrointestinalCardiovascularRespiratoryAnti-inflammatory

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular

Essential Hypertension

SPC 2003 SPC1001 Low SPC5002 SPC5003 SPC5004

Ischemic Stroke

SP-8203

Cardiovascular

Essential Hypertension

SPC 2003Phase 2

SPC1001 LowPhase 2

SPC5002Phase 2

SPC5003Phase 2

SPC5004Phase 2

Ischemic Stroke

SP-8203Phase 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)